Centro de Estudios Clínicos e Investigación Médica (CeCim)
About Centro de Estudios Clínicos e Investigación Médica (CeCim)
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Clinical Trials at Centro de Estudios Clínicos e Investigación Médica (CeCim)
During the past decade, Centro de Estudios Clínicos e Investigación Médica (CeCim) conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 2 clinical trials were completed, i.e. on
average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 1 clinical trials were completed. i.e. 11.1%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
2004-08-01
2009-05-01
Completed
100
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
2008-09-03
2016-02-25
Completed
723
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
2010-01-01
2015-12-01
Completed
1,069
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
2009-09-01
2016-01-01
Completed
347
Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy
2009-09-30
2017-11-02
Completed
1,199
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
2011-01-13
2016-11-30
Completed
343
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
2012-11-23
2019-02-12
Completed
156
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)
2013-02-22
2023-08-26
Active, not recruiting
666
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Centro de Estudios Clínicos e Investigación Médica (CeCim)" #1 sponsor was "Janssen Research & Development, LLC" with 4 trials, followed by "Janssen Vaccines & Prevention B.V." with 2 trials
sponsored, "Boehringer Ingelheim" with 1 trials sponsored, "CanariaBio Inc." with 1 trials sponsored and "Hoffmann-La Roche"
with 1 trials sponsored. Other sponsors include -3 different institutions and
companies that sponsored additional 7 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Centro de Estudios Clínicos e Investigación Médica (CeCim)"
#1 collaborator was "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "Gynecologic Oncology Group" with 1 trials as a collaborator and "Iqvia Pty Ltd" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were
collaborators in the rest 4 trials.
Clinical Trials Conditions at Centro de Estudios Clínicos e Investigación Médica (CeCim)
According to Clinical.Site data, the most researched conditions in "Centro de Estudios Clínicos e Investigación Médica (CeCim)" are
"Crohn's Disease" (2 trials), "Depressive Disorder, Major" (2 trials), "Carcinoma, Ovarian Epithelial" (1 trials), "Colitis, Ulcerative" (1 trials) and "Diabetes Mellitus, Type 2" (1 trials). Many other conditions were trialed in "Centro de Estudios Clínicos e Investigación Médica (CeCim)" in a lesser frequency.
Clinical Trials Intervention Types at Centro de Estudios Clínicos e Investigación Médica (CeCim)
Most popular intervention types in "Centro de Estudios Clínicos e Investigación Médica (CeCim)" are "Drug" (9 trials), "Biological" (5 trials) and "Other" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (9 trials), "Golimumab" (2 trials), "Guselkumab" (2 trials), "JNJ-78934804" (2 trials) and "Seltorexant" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Centro de Estudios Clínicos e Investigación Médica (CeCim)
The vast majority of trials in "Centro de Estudios Clínicos e Investigación Médica (CeCim)" are
10 trials for "All" genders and 1 trials for "Female" genders.
Clinical Trials Status at Centro de Estudios Clínicos e Investigación Médica (CeCim)
Currently, there are NaN active trials in "Centro de Estudios Clínicos e Investigación Médica (CeCim)".
undefined are not yet recruiting,
8 are recruiting,
1 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 1 completed trials in Centro de Estudios Clínicos e Investigación Médica (CeCim),
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in Centro de Estudios Clínicos e Investigación Médica (CeCim), 0 "Phase 1"
clinical trials were conducted, 3 "Phase 2" clinical
trials and 7 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 1 trials, and there were
also 0 trials that are defined as “Not Applicable".